These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34156022)

  • 1. SHORT- AND LONG-TERM EFFECTS OF NSAIDS ON THE GASTROINTESTINAL MUCOSA: COMPLEX ANALYSIS OF BENEFITS AND COMPLICATIONS PREVENTION.
    Hnepa YY; Chopey IV; Chubirko KI; Bratasyuk AM
    Wiad Lek; 2021; 74(4):1011-1018. PubMed ID: 34156022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?
    Adebayo D; Bjarnason I
    Postgrad Med J; 2006 Mar; 82(965):186-91. PubMed ID: 16517800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly.
    Lanas A; Ferrandez A
    Drugs Aging; 2007; 24(2):121-31. PubMed ID: 17313200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment and prevention of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs.
    Lane ME; Kim MJ
    J Pharm Pharmacol; 2006 Oct; 58(10):1295-304. PubMed ID: 17034651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy.
    Bielsa-Fernández MV; Tamayo-de la Cuesta JL; Lizárraga-López J; Remes-Troche JM; Carmona-Sánchez R; Aldana-Ledesma JM; Avendaño-Reyes JM; Ballesteros-Amozorrutia MA; De Ariño M; de Giau-Triulzi L; Flores-Rendón R; Huerta-Guerrero H; González-González JA; Hernández-Guerrero A; Murcio-Pérez E; Jáquez-Quintana JO; Meixueiro-Daza A; Nogueira-de Rojas JR; Rodríguez-Hernández H; Santoyo-Valenzuela R; Solorzano-Olmos SC; Uscanga-Domínguez LF; Zamarripa-Dorsey F
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(2):190-206. PubMed ID: 32094057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAID-related gastrointestinal complications.
    Soll AH; McCarthy D
    Clin Cornerstone; 1999; 1(5):42-56. PubMed ID: 10682181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.
    Becker JC; Domschke W; Pohle T
    Br J Clin Pharmacol; 2004 Dec; 58(6):587-600. PubMed ID: 15563357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes.
    van Leen MW; van der Eijk I; Schols JM
    Age Ageing; 2007 Jul; 36(4):414-8. PubMed ID: 17537740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [NSAID GASTROPATHY IN PATIENTS WITH COMORBID DISEASES].
    Morozova TE; Rykova SM; Chukina MA
    Eksp Klin Gastroenterol; 2015; (6):64-70. PubMed ID: 26817107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [NSAID-induced gastroenteropathy].
    Kim JW
    Korean J Gastroenterol; 2008 Sep; 52(3):134-41. PubMed ID: 19077509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI].
    Lems WF; Kuipers EJ
    Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies.
    Graumlich JF
    Postgrad Med; 2001 May; 109(5):117-20, 123-8. PubMed ID: 11381661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
    Lanas A; Ferrandez A
    Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy.
    Roth SH
    Drugs; 2012 May; 72(7):873-9. PubMed ID: 22564130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
    Johnell K; Fastbom J
    Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacist intervention reduces gastropathy risk in patients using NSAIDs.
    Ibañez-Cuevas V; Lopez-Briz E; Guardiola-Chorro MT;
    Pharm World Sci; 2008 Dec; 30(6):947-54. PubMed ID: 18932013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.